Scarica l'app Stockscreener
13.80
1.22%
-0.17
Dopo l'orario di chiusura:
13.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$13.97
Aprire:
$13.77
Volume 24 ore:
13.43M
Relative Volume:
1.35
Capitalizzazione di mercato:
$15.89B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-4.3533
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
-5.02%
1M Prestazione:
-12.60%
6M Prestazione:
+38.55%
1 anno Prestazione:
+49.35%
Intervallo 1D:
$13.62
$13.93
Intervallo di 1 settimana:
$13.62
$14.52
Portata 52W:
$6.85
$16.47
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
13.80 | 16.08B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 57.24B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.46 | 50.57B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.07 | 44.54B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.30 | 35.49B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
532.82 | 23.87B | 3.13B | 1.27B | 1.12B | 26.39 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst - TipRanks
Viatris resolves case over use of woman’s cancer cells (VTRS) - Seeking Alpha
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research - Reuters
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Viatris Collaborates With GoodRx for Discounts of Up to 85% on Medications - marketscreener.com
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications - Business Wire
Trading Systems Reacting to (VTRS) Volatility - Stock Traders Daily
Propranolol Market Overall Study Report 2026-2033 | Teva - openPR.com
Viatris Stock Analysis: Strong 6-Month Gains vs. Poor 5-Year FundamentalsNews and Statistics - IndexBox
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
Viatris (VTRS): Should You Buy, Sell, or Hold After Q4 Results? - Bitget
Viatris Inc. (VTRS) provides updates on four recent regulatory milestones - MSN
Viatris Eyes Specialty Shift As FDA Reviews MR-141 Presbyopia Drug - Yahoo Finance
Viatris tops forecasts as earnings and revenue beat expectations - MSN
Goldman Sachs Adjusts Price Target on Viatris to $14 From $13, Maintains Neutral Rating - marketscreener.com
FDA Review Of MR-141 Puts Viatris Ophthalmic Growth Story In Focus - Sahm
Better Value & Growth: LLY, JNJ Top Viatris Stock - Trefis
Ex-Dividend Reminder: Alphabet, Constellation Energy and Viatris - Nasdaq
Viatris Stock Hits Day Low of $15.14 Amid Price Pressure - Markets Mojo
Viatris, Inc. Hits New 52-Week High at USD 16.46 - Markets Mojo
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq
Viatris Unit Can't Ax Patent For Anemia Drug Evrenzo - Law360
Generic Pharma Q4 2025 Earnings Review: Revenue Beat, Stock DeclineNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive - FinancialContent
VTRS Financials: Income Statement, Balance Sheet & Cash Flow | Viatris Inc Ord Shs - Stock Titan
A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review - simplywall.st
Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value - Finviz
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Report: Navigating the Healthcare Giant’s 3.22% Dividend Yield and Revenue Growth - DirectorsTalk Interviews
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 - Finviz
Viatris Earnings Call Highlights Slow Growth, Cash Strength - TipRanks
UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve - Insider Monkey
UBS raises Viatris stock price target to $20 on cost savings - Investing.com India
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com
Viatris Inc. (NASDAQ:VTRS) Q4 2025 Earnings Call Transcript - Insider Monkey
Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date - Finviz
JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating - marketscreener.com
A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update - Yahoo Finance
Decoding Viatris Inc (VTRS): A Strategic SWOT Insight - GuruFocus
Viatris Earnings: Drugmaker Left 2025 With Momentum; 2026 to Bring Stability and Broad-Based Growth - Morningstar
Viatris: Q4 Earnings Snapshot - theheraldreview.com
BofA raises Viatris stock price target on cost-cutting plan - Investing.com
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Is Strong Q4 Revenue And Steady Dividend Policy Altering The Investment Case For Viatris (VTRS)? - simplywall.st
Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives - Morningstar
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Finviz
Earnings call transcript: Viatris Q4 2025 earnings beat forecasts, stock up - Investing.com
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan - Investing.com
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):